Bullboard - Stock Discussion Forum Moleculin Biotech Inc MBRX

Healthcare Biotechnology

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug... see more

Add To Watchlist

NDAQ:MBRX - Post Discussion

Moleculin Biotech Inc > Moleculin Announces 2023 Year-End Annamycin Clinical Trials

View:

Post by whytestocks on Jan 24, 2024 2:00pm

Moleculin Announces 2023 Year-End Annamycin Clinical Trials

News; $MBRX Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 PR Newswire – MB-106 AML Phase 1B /2 trial (MB-106) preliminary data readout: Reached 67% recruitment ...MBRX - Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Comment

Comment by Dormie18 on Jul 04, 2024 9:55pm

Klemp said a meeting with the FDA had been scheduled for June to discuss the results to date for MB-106 and design the Phase 2B/3 trial which might start as early as late 2024. Klemp said he would report to shareholders the results of the meeting with the FDA in Q3. I'm in. We wait.

Comment

Moleculin Biotech Inc